Gapping down
In reaction to earnings/guidance:
- SPNE -7% (lowers guidance)
Other news:
- ASLN -25.8% (reports new data for ASLAN004)
- BHVN -6.3% (reports Verdiperstat did not meet primary endpoints)
- VNRX -6.2% (files for $100 mln mixed securities shelf offering)
- OPK -4.5% (Opko Health and Pfizer (PFE) announce extension of FDA review of BLA for somatrogon for pediatric growth hormone deficiency)
- OPAD -1.8% (files for 237,268,350 share common stock offering by selling shareholders)
Analyst comments:
- ZY -3.1% (downgraded to Underweight from Neutral at JP Morgan)
- RIDE -2.2% (downgraded to Sell from Neutral at Goldman)
- NFBK -1.9% (downgraded to Neutral from Overweight at Piper Sandler)
- TLIS -1.8% (downgraded to Underweight from Neutral at JP Morgan)
- ATUS -1.6% (downgraded to Neutral from Outperform at Credit Suisse; downgraded to Mkt Perform from Outperform at Raymond James)